You are here

Bio-Filtration Device Helps Eradicate Virus in Ebola Patient

German hospital tries investigational treatment

Officials at Frankfurt University Hospital in Germany have reported undetectable virus in an Ebola patient who had been treated with an investigational bio-filtration device.

According to an article in the Wall Street Journal, hospital officials indicated that the patient is no longer infected with Ebola virus and is heading toward a full recovery.

The Hemopurifier is a first-in-class bio-filtration device that eliminates viruses and immunosuppressive proteins from the circulatory system of infected individuals.

At present, no antiviral therapy or vaccine has been shown to be effective against Ebola virus infection in humans. According to the World Health Organization (WHO), more than 5,000 deaths have been attributed to the current Ebola virus epidemic.

The patient at Frankfurt University Hospital received Hemopurifier therapy through special approval from the Federal Institute for Drugs and Medical Devices, an independent authority within Germany’s Federal Ministry of Health.

According to the device’s developer (Aethlon Medical, Inc.), the Hemopurifier targets two unmet medical needs in Ebola patients: the rapid elimination of circulating viruses to inhibit continued replication of virus progeny, and the direct targeting of shed glycoproteins, which can overwhelm the host’s immune response. The device can be deployed for use within the global infrastructure of dialysis and continuous renal replacement therapy machines already located in hospitals and clinics.

Aethlon is preparing to initiate U.S. clinical studies of Hemopurifier therapy, based on the FDA’s approval of an investigational device exemption that was previously submitted by the company. The study will contribute safety data to advance the device as a broad-spectrum countermeasure against pandemic threats, including Ebola and chronic viral pathogens, such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV).

To date, Hemopurifier therapy has been administered in approximately 100 treatment experiences in health-compromised HIV- and HCV-infected individuals. These studies were conducted in India. In vitro validation studies that demonstrated the ability of the Hemopurifier to capture Zaire and other strains of Ebola virus were conducted by researchers at the U.S. Army Medical Research Institute for Infectious Diseases and at the Centers for Disease Control and Prevention.

 Sources: Aethlon Medical, Inc.; November 6, 2014; and Aethlon Hemopurifier; 2012.

Recent Headlines

Two-Thirds of U.S. Alzheimer’s Cases Are Women, And It’s Not Just Because They Live Longer
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
Breast Cancer, Gastrointestinal Tumors Most Common Types
NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens